Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP5 | P45974 | 4/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | IKBKB | O14920 | 4/20 | 0.33 |
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771111 | 0.93 | CNR1 (0.37) | USP5HDAC6ALDH1A1IKBKBCNR1 | |
| SCHEMBL771628 | 0.86 | ALDH1A1 (0.36) | ALDH1A1IKBKBSMYD3 | |
| SCHEMBL770956 | 0.86 | ATM (0.37) | ALDH1A1MEN1KMT2A | |
| SCHEMBL772378 | 0.86 | ATM (0.37) | ALDH1A1MEN1KMT2A | |
| SCHEMBL771023 | 0.86 | ATM (0.37) | ALDH1A1MEN1KMT2A | |
| SCHEMBL771013 | 0.84 | CHRM2 (0.34) | ALDH1A1IKBKB | |
| SCHEMBL770773 | 0.83 | POLB (0.32) | ALDH1A1SMYD3 | |
| SCHEMBL771175 | 0.83 | NPC1 (0.45) | ALDH1A1MEN1KMT2A | |
| SCHEMBL770914 | 0.82 | HDAC1 (0.33) | — | |
| SCHEMBL770781 | 0.82 | PDE3B (0.39) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2439202-B1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | SALVAT LAB SA (ES) | 2016-04-20 | — | — | EP | disclosed |
| US-8524894-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | USP5 2546/4885HDAC6 2411/4885ALDH1A1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.